Emerging Metabolic Targets in the Therapy of Hematological Malignancies

Table 2

Summary of preclinical studies and ongoing clinical trials with glycolysis inhibitors.

Drug	Target	Group or cell lines	Phase	Reference
2-DG	HK	Lung, breast, head and neck, pancreatic, and gastric cancers	Completed in 2009	[134]
2-DG	HK	Patients with advanced cancer and hormone refractory prostate cancer	Completed in 2011	[135]
3-BrPA	HK	Childhood acute lymphoblastic leukemia cell lines	Preclinical	[110, 121]
FX11	LDH-A	Tumor growth	Preclinical	[92]

2-Deoxyglucose (2-DG), 3-bromopyruvate (3-BrPA), (FX11 [3-dihydroxy-6-methyl-7-(phenylmethyl)-4-propylnaphthalene-1-carboxilic acid]) (FX11), and dichloroacetate (DCA). Information was retrieved from http://www.ncbi.nlm.nih.gov/pubmed.